Elutia Inc. (NASDAQ:ELUT) — Market Cap & Net Worth
Market Cap & Net Worth: Elutia Inc. (ELUT)
Elutia Inc. (NASDAQ:ELUT) has a market capitalization of $40.75 Million ($40.75 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22625 globally and #4744 in its home market, demonstrating a -7.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elutia Inc.'s stock price $1.01 by its total outstanding shares 40349939 (40.35 Million). Analyse Elutia Inc. operating cash flow efficiency to see how efficiently the company converts income to cash.
Elutia Inc. Market Cap History: 2020 to 2026
Elutia Inc.'s market capitalization history from 2020 to 2026. Data shows change from $549.97 Million to $40.75 Million (-38.05% CAGR).
Index Memberships
Elutia Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #649 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2165 of 3165 |
Weight: Elutia Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elutia Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elutia Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.19x
Elutia Inc.'s market cap is 6.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $549.97 Million | $42.68 Million | -$21.82 Million | 12.89x | N/A |
| 2021 | $254.20 Million | $47.39 Million | -$24.83 Million | 5.36x | N/A |
| 2022 | $171.49 Million | $23.85 Million | -$32.90 Million | 7.19x | N/A |
| 2023 | $87.16 Million | $24.75 Million | -$37.66 Million | 3.52x | N/A |
| 2024 | $150.91 Million | $24.38 Million | -$53.95 Million | 6.19x | N/A |
Competitor Companies of ELUT by Market Capitalization
Companies near Elutia Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Elutia Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Elutia Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Elutia Inc.'s market cap moved from $549.97 Million to $ 40.75 Million, with a yearly change of -38.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $40.75 Million | +45.81% |
| 2025 | $27.95 Million | -81.48% |
| 2024 | $150.91 Million | +73.15% |
| 2023 | $87.16 Million | -49.18% |
| 2022 | $171.49 Million | -32.54% |
| 2021 | $254.20 Million | -53.78% |
| 2020 | $549.97 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Elutia Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.75 Million USD |
| MoneyControl | $40.75 Million USD |
| MarketWatch | $40.75 Million USD |
| marketcap.company | $40.75 Million USD |
| Reuters | $40.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators;… Read more